Phosphorus fractions and its potential release in the sediments of Koycegiz Lake, Turkey

This study was conducted to find out the seasonal and spatial patterns of the phosphorus in the littoral sediment and its potential release into the Koycegiz Lake, south west Turkey, between November 2011 and March 2012 at two months intervals. The scanning electron microscopy was used for elemental compositions of the sediment. The amounts and forms of phosphorus (P) in surface sediments of Koycegiz Lake were examined using a not sequential chemical extraction procedure. Four fractions of sedimentary P, including organic bound phosphorus fraction (Org≈P), calcium bound phosphorus fraction (Ca≈P), iron+aluminium bound phosphorus fraction (Fe+Al≈P) and carbonate bound phosphorus fraction (CO3≈P) were separately quantified. The results indicated that the contents of different phosphorus fractions in the sediments varied greatly. The proportion of phosphorus fractions was estimated as Org≈P (90.20 %), this fraction was followed by Ca≈P) (9.06 %), Fe+Al≈P (0.47 %) and CO3≈P (0.27 %) in this study. The level of phosphorus release from the sediment to the lake is calculated as low. The sediment phosphorus release fluctuated between -6.647–75.883 μg/m2.d-1 and the total phosphorus (TP) concentrations of the sediment samples were changed between 980.39 μg/gDW (Dry Weight) - 1990.81 μg/gDW. The results show that it can be evaluation as eutrophic for Koycegiz Lake

Antioxidant Effects of Probiotics in Experimentally Induced Peritonitis

Aim: An experimental study was performed to evaluate the protective effects of probiotics on gut mucosa in peritonitis through antioxidant mechanisms. Methods: Thirty-two male Wistar albino rats were divided equally into four groups. The rats in Group 1 (control group) underwent laparotomy only. In group 2 (peritonitis group), peritonitis was induced in the rats by the cecal ligation and puncture (CLP) model. In group 3, the rats were treated with probiotics for five days after CLP-induced peritonitis. The last group of rats (group 4) were fed probiotics for five days before the CLP procedure and five days after the surgery. On the fifth day after surgery, all rats were killed, and tissue samples from the terminal ileum were obtained to evaluate the activities of myeloperoxidase (MPO), malondialdehyde (MDA), and glutathione (GSH). Histopathologic examinations were also performed to evaluate the grade of intestinal injury. Results: Myeloperoxidase and MDA activities were increased, GSH concentrations were decreased in group 2, compared with group 1. Intestinal MPO activities in group 4 were decreased compared with group 1 and group 2, indicating a reduction in oxidant activity. Malondialdehyde decreased in group 3 and decreased even more in group 4, compared with the peritonitis group (group 2). Glutathione concentrations were increased in group 4 compared with group 2 and group 3 (p<0.05). The Chiu scores of the probiotics groups, groups 3 and 4, were lower than those in group 2, indicating reduced mucosal damage in the probiotically fed groups. Conclusion: Probiotics have protective effects in peritonitis, which may be related to antioxidant mechanisms. This antioxidant effect of probiotics might occur when pre-conditioning with probiotics before peritonitis because there is sufficient time to prepare the tissues for oxidative damage

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia